Sickle cell disease (SCD), iNKT cells, and regadenoson infusion.

Transactions of the American Clinical and Climatological Association

Volumn 123, Issue , 2012, Pages

  Nathan, David G ^a   Field, Joshua ^b   Lin, Gene ^b   Neuberg, Donna ^b   Majerus, Elaine ^b   Onyekwere, Onyinye ^b   Keefer, Jeffrey ^b   Okam, Maureen ^b   Ross, Ainsley ^b   Linden, Joel ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2 RECEPTOR AGONIST; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE; REGADENOSON;

ARTICLE; CELL COUNT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NATURAL KILLER T CELL; PATHOLOGY; PHASE 2 CLINICAL TRIAL; REMISSION; SICKLE CELL ANEMIA; TIME; TREATMENT OUTCOME;

ADENOSINE A2 RECEPTOR AGONISTS; ANEMIA, SICKLE CELL; CELL COUNT; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFUSIONS, INTRAVENOUS; NATURAL KILLER T-CELLS; PURINES; PYRAZOLES; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879475046     PISSN: 00657778     EISSN: None     Source Type: None    
DOI: None     Document Type: Article

References (0)